vs
Apellis Pharmaceuticals, Inc.（APLS）与COGENT COMMUNICATIONS HOLDINGS, INC.（CCOI）财务数据对比。点击上方公司名可切换其他公司
COGENT COMMUNICATIONS HOLDINGS, INC.的季度营收约是Apellis Pharmaceuticals, Inc.的1.2倍（$240.5M vs $199.9M），COGENT COMMUNICATIONS HOLDINGS, INC.净利率更高（-12.8% vs -29.5%，领先16.7%），COGENT COMMUNICATIONS HOLDINGS, INC.同比增速更快（-4.7% vs -5.9%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-43.0M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -4.9%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
高智通信控股公司是总部设在美国的跨国互联网服务供应商，核心业务包括光纤IP专用网络下的互联网接入与数据传输服务，同时也提供数据中心服务器托管业务，在全球互联网基础设施领域拥有广泛的业务布局。
APLS vs CCOI — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $240.5M |
| 净利润 | $-59.0M | $-30.8M |
| 毛利率 | — | 46.6% |
| 营业利润率 | -25.6% | -4.7% |
| 净利率 | -29.5% | -12.8% |
| 营收同比 | -5.9% | -4.7% |
| 净利润同比 | -62.2% | 28.9% |
| 每股收益（稀释后） | $-0.40 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $240.5M | ||
| Q3 25 | $458.6M | $241.9M | ||
| Q2 25 | $178.5M | $246.2M | ||
| Q1 25 | $166.8M | $247.0M | ||
| Q4 24 | $212.5M | $252.3M | ||
| Q3 24 | $196.8M | $257.2M | ||
| Q2 24 | $199.7M | $260.4M | ||
| Q1 24 | $172.3M | $266.2M |
| Q4 25 | $-59.0M | $-30.8M | ||
| Q3 25 | $215.7M | $-41.5M | ||
| Q2 25 | $-42.2M | $-57.8M | ||
| Q1 25 | $-92.2M | $-52.0M | ||
| Q4 24 | $-36.4M | $-43.3M | ||
| Q3 24 | $-57.4M | $-63.1M | ||
| Q2 24 | $-37.7M | $-32.3M | ||
| Q1 24 | $-66.4M | $-65.3M |
| Q4 25 | — | 46.6% | ||
| Q3 25 | — | 45.6% | ||
| Q2 25 | — | 44.2% | ||
| Q1 25 | — | 44.4% | ||
| Q4 24 | — | 38.5% | ||
| Q3 24 | — | 37.2% | ||
| Q2 24 | — | 40.0% | ||
| Q1 24 | — | 36.5% |
| Q4 25 | -25.6% | -4.7% | ||
| Q3 25 | 48.7% | -7.5% | ||
| Q2 25 | -18.6% | -12.8% | ||
| Q1 25 | -50.0% | -16.3% | ||
| Q4 24 | -12.3% | -13.2% | ||
| Q3 24 | -24.0% | -22.5% | ||
| Q2 24 | -14.7% | -18.1% | ||
| Q1 24 | -36.0% | -22.3% |
| Q4 25 | -29.5% | -12.8% | ||
| Q3 25 | 47.0% | -17.2% | ||
| Q2 25 | -23.6% | -23.5% | ||
| Q1 25 | -55.3% | -21.1% | ||
| Q4 24 | -17.1% | -17.2% | ||
| Q3 24 | -29.2% | -24.5% | ||
| Q2 24 | -18.9% | -12.4% | ||
| Q1 24 | -38.5% | -24.5% |
| Q4 25 | $-0.40 | $-0.63 | ||
| Q3 25 | $1.67 | $-0.87 | ||
| Q2 25 | $-0.33 | $-1.21 | ||
| Q1 25 | $-0.74 | $-1.09 | ||
| Q4 24 | $-0.30 | $-0.89 | ||
| Q3 24 | $-0.46 | $-1.33 | ||
| Q2 24 | $-0.30 | $-0.68 | ||
| Q1 24 | $-0.54 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $148.5M |
| 总债务越低越好 | — | $1.7B |
| 股东权益账面价值 | $370.1M | $-63.8M |
| 总资产 | $1.1B | $3.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $148.5M | ||
| Q3 25 | $479.2M | $147.1M | ||
| Q2 25 | $370.0M | $213.7M | ||
| Q1 25 | $358.4M | $153.8M | ||
| Q4 24 | $411.3M | $198.5M | ||
| Q3 24 | $396.9M | $279.2M | ||
| Q2 24 | $360.1M | $384.4M | ||
| Q1 24 | $325.9M | $118.4M |
| Q4 25 | — | $1.7B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $-63.8M | ||
| Q3 25 | $401.2M | $-39.2M | ||
| Q2 25 | $156.3M | $46.7M | ||
| Q1 25 | $164.2M | $142.8M | ||
| Q4 24 | $228.5M | $222.8M | ||
| Q3 24 | $237.1M | $323.6M | ||
| Q2 24 | $264.3M | $415.5M | ||
| Q1 24 | $266.7M | $500.6M |
| Q4 25 | $1.1B | $3.1B | ||
| Q3 25 | $1.1B | $3.1B | ||
| Q2 25 | $821.4M | $3.3B | ||
| Q1 25 | $807.3M | $3.1B | ||
| Q4 24 | $885.1M | $3.2B | ||
| Q3 24 | $901.9M | $3.2B | ||
| Q2 24 | $904.5M | $3.3B | ||
| Q1 24 | $831.9M | $3.1B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.53× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-6.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-43.0M |
| 自由现金流率自由现金流/营收 | -7.1% | -17.9% |
| 资本支出强度资本支出/营收 | 0.1% | 15.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-198.1M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $-6.0M | ||
| Q3 25 | $108.5M | $3.1M | ||
| Q2 25 | $4.4M | $-44.0M | ||
| Q1 25 | $-53.4M | $36.4M | ||
| Q4 24 | $19.4M | $14.5M | ||
| Q3 24 | $34.1M | $-20.2M | ||
| Q2 24 | $-8.3M | $-22.2M | ||
| Q1 24 | $-133.0M | $19.2M |
| Q4 25 | $-14.3M | $-43.0M | ||
| Q3 25 | $108.3M | $-33.1M | ||
| Q2 25 | $4.4M | $-100.2M | ||
| Q1 25 | $-53.4M | $-21.7M | ||
| Q4 24 | $19.3M | $-31.6M | ||
| Q3 24 | — | $-79.5M | ||
| Q2 24 | $-8.4M | $-70.9M | ||
| Q1 24 | $-133.3M | $-21.7M |
| Q4 25 | -7.1% | -17.9% | ||
| Q3 25 | 23.6% | -13.7% | ||
| Q2 25 | 2.5% | -40.7% | ||
| Q1 25 | -32.0% | -8.8% | ||
| Q4 24 | 9.1% | -12.5% | ||
| Q3 24 | — | -30.9% | ||
| Q2 24 | -4.2% | -27.2% | ||
| Q1 24 | -77.3% | -8.1% |
| Q4 25 | 0.1% | 15.4% | ||
| Q3 25 | 0.0% | 15.0% | ||
| Q2 25 | 0.0% | 22.8% | ||
| Q1 25 | 0.0% | 23.5% | ||
| Q4 24 | 0.0% | 18.3% | ||
| Q3 24 | 0.0% | 23.0% | ||
| Q2 24 | 0.0% | 18.7% | ||
| Q1 24 | 0.2% | 15.4% |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CCOI
暂无分部数据
